Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.

Presentation

Optimizing Dermatologic Care: Melasma Treatment, Tranexamic Acid, and Filler Safety

Description

The speaker shared practical dermatology pearls focused on improving clinic workflow, combining treatments safely, and managing melasma and filler complications. In practice, she emphasized building a strong team, reviewing schedules in advance, using paid consultations, holding daily huddles, and delegating price discussions and quote sheets to staff. She discussed treatment sequencing and noted that neuromodulators can often be done the same day as certain lasers, while botulinum toxin before laser may improve outcomes; botulinum toxin and fillers can also be performed together, but mixing them in one syringe raises sterility concerns. For melasma, she stressed that it is chronic and especially common in skin of color, with first-line management centered on sun avoidance, mineral sunscreen, and visible-light protection with iron oxide, followed by topical therapy such as the triple combination cream. She described oral tranexamic acid as an important option before lasers, outlined clot-risk screening, and noted that routine lab work is usually unnecessary. She also highlighted case-based cautions, including temporary vision loss with tranexamic acid that resolved after stopping the drug, and pigmentation changes in patients who had glutathione infusions. Laser approaches for pigment disorders should favor non-melanin-targeting, low-fluence short-pulse devices, with awareness of hypopigmentation risk. Finally, she reviewed a study on filler-related neurologic complications, finding that severe outcomes were most often associated with injections in high-risk areas such as the nose, forehead, and glabella rather than total dose, and advised caution, slow technique, and avoiding these regions when possible.

View more

Conclusions

Multimodal cosmetic care works best when the practice is organized, the team is prepared, and pricing and consent processes are handled clearly and consistently.
Same-day combinations of neuromodulators with nonablative lasers, and often with fillers, appear generally safe and can improve workflow and patient satisfaction when used thoughtfully.
For melasma, foundational photoprotection and lifestyle modification should come before topical therapy, oral tranexamic acid, and lasers.
A modified triple topical regimen with hydroquinone, tretinoin, and a steroid remains a strong first-line medical treatment for melasma.
Oral tranexamic acid can be highly effective for melasma, but clinicians should perform careful history-based risk stratification for thrombotic events and hormone-related risks.
Routine laboratory coagulation testing is not usually necessary before starting tranexamic acid if the clinical history does not suggest elevated risk.
Glutathione use, especially IV formulations and after resurfacing or laser procedures, may alter pigmentation patterns and can contribute to unusual yellow-red or pheomelanin-dominant pigment changes.
For refractory pigmentation disorders, low-fluence, short-pulse 1064 nm laser strategies can help, but more frequent treatment increases the risk of hypopigmentation and other adverse effects.
Filler-associated neurologic and visual complications are rare but often severe, with poor recovery in many cases.
Injection site appears to be a stronger predictor of filler complication risk and recovery than total filler dose, with the nose, forehead, and glabella representing particularly high-risk areas.
Hyaluronic acid is the most common filler involved in reported complications, but autologous fat may carry disproportionate risk relative to its use.
Because outcomes after vascular or neurologic filler complications are often limited, prevention and cautious technique are more important than rescue.
The overall clinical message is to use multimodal cosmetic treatments deliberately, sequence them intelligently, and avoid rushing into high-risk procedures or injection sites.

BMJ 2019 study on hormone replacement therapy and venous thromboembolism risk.#10.1136/bmj.39556.666944.80
Sarkar et al., Int J Dermatology (2024).
Lu et al., Bioscience Reports (2021).
Aesth Plast Surg (2024) 48:3222-3253.